Rhinitis, Allergic: Clinical Trials

7 trials for Rhinitis, Allergic, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 2 unknown, 1 terminated. 7 Early Phase 1.

By phase and status

PhaseTrialsStatus
Early Phase 17Completed 4, Unknown 2, Terminated 1

Follow Rhinitis, Allergic: new trials by email Literature Review of Rhinitis, Allergic trials Research Report on Rhinitis, Allergic

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Combination of Oral Supplement With Fatty Acids, Vitamin B6, Perilla, and Liquorice With Nasal Steroids for the Treatment of Allergic Rhinitis
Oral fatty acid, Mometasone Furoate Nasal Spray (MFNS) - Allergic Rhinitis
Early Phase 1CompletedIsola Tiberina - Gemelli Isola Hospital, Rome, Italy4002024-09-012025-06-12
Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study
Polvac Grass+Rye - Hypersensitivity, Hay Fever
Early Phase 1CompletedUniversity of Zurich282023-11-232025-05-21
Prospective Multicenter Observational Study and Promotion of the Application of Focused Ultrasound in Allergic Rhinitis
High-intensity focused ultrasound (HIFU), intranasal corticosteroids, oral antihistamines, oral leukotriene receptor antagonists, and intranasal antihistamines - Allergic Rhinitis
Early Phase 1UnknownChongqing Medical University2402023-08-012024-02-22
Impact Of Montelukast On Allergic Rhinitis And Its Inflammatory Makers
Montelukast Oral Tablet - Allergic Rhinitis
Early Phase 1UnknownAssiut University602022-10-012022-05-19
Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders
HP 3He, HP 129Xe, PFP - Lung Transplant, Lung Resection
Early Phase 1TerminatedThunder Bay Regional Health Research Institute102020-11-102024-10-15
Compare the Effect of INS Alone and Added LTRA in Treatment of SAR
budesonide - Allergic Rhinitis
Early Phase 1CompletedBeijing Tongren Hospital462016-06-012019-09-04
Study of a Topical Nasal Spray to Ease the Symptoms of Hayfever
C-1266-7, C-1266-6 (placebo) - Rhinitis, Allergic, Seasonal
Early Phase 1CompletedMcNeil Consumer Healthcare Division of McNEIL-PPC, Inc.212012-01-012017-02-27

Narrower conditions

Rhinitis, Allergic, Seasonal (3)  ·  Asbestosis (1)  ·  Asthma (1)  ·  Bronchiectasis (1)  ·  Cystic Fibrosis (1)  ·  Emphysema (1)  ·  Hypersensitivity (1)  ·  Hypertension, Pulmonary (1)  ·  Lung Diseases, Interstitial (1)  ·  Lung Neoplasms (1)  ·  Mesothelioma (1)  ·  Pulmonary Disease, Chronic Obstructive (1)  ·  Pulmonary Embolism (1)  ·  Pulmonary Fibrosis (1)

Broader conditions

Hypersensitivity, Immediate (7)  ·  Immune System Diseases (7)  ·  Nose Diseases (7)  ·  Otorhinolaryngologic Diseases (7)  ·  Respiratory Hypersensitivity (7)  ·  Respiratory Tract Diseases (7)  ·  Rhinitis (7)  ·  Hypersensitivity (6)  ·  Adenoma (1)  ·  Apnea (1)  ·  Bronchial Diseases (1)  ·  Cardiovascular Diseases (1)  ·  Chronic Disease (1)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)

Interventions

montelukast (2)  ·  Budesonide (1)  ·  Fatty Acids (1)  ·  Histamine Antagonists (1)  ·  Leukotriene Antagonists (1)  ·  Long-Term Synaptic Depression (1)  ·  Sulfur Hexafluoride (1)  ·  perflutren (1)

Sponsors

Assiut University (1)  ·  Beijing Tongren Hospital (1)  ·  Chongqing Medical University (1)  ·  Isola Tiberina - Gemelli Isola Hospital, Rome, Italy (1)  ·  McNeil Consumer Healthcare Division of McNEIL-PPC, Inc. (1)  ·  Thunder Bay Regional Health Research Institute (1)  ·  University of Zurich (1)

Countries

China (2)  ·  Canada (1)  ·  Italy (1)  ·  Switzerland (1)  ·  United States (1)

Top investigators

Daniel S Qi, MD, PhD (1)  ·  Mitchell S Albert, PhD (1)  ·  Peter Schmid-Grendelmeier, Prof. MD (1)  ·  Shen Yang, Doctoral (1)  ·  Zhang Luo (1)

Results publications

PMID 19001265, PMID 32679209, PMID 33099797, PMID 35584850, PMID 35762891

NIH funding

2023 (1)